Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder in remission and healthy first degree relatives with cognitive impairments (PRETEC-EPO)

Trial Profile

Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder in remission and healthy first degree relatives with cognitive impairments (PRETEC-EPO)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Bipolar disorders
  • Focus Therapeutic Use
  • Acronyms PRETEC-EPO
  • Most Recent Events

    • 25 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top